Assetmark Inc. Purchases 11,928 Shares of IQVIA Holdings Inc. $IQV

Assetmark Inc. boosted its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 10.2% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 129,189 shares of the medical research company’s stock after acquiring an additional 11,928 shares during the quarter. Assetmark Inc. owned 0.08% of IQVIA worth $24,538,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of IQV. Artisan Partners Limited Partnership purchased a new stake in shares of IQVIA during the second quarter valued at $515,772,000. Norges Bank bought a new position in IQVIA during the 2nd quarter valued at about $270,160,000. AQR Capital Management LLC boosted its holdings in shares of IQVIA by 130.2% during the 2nd quarter. AQR Capital Management LLC now owns 1,555,298 shares of the medical research company’s stock valued at $245,099,000 after acquiring an additional 879,701 shares during the last quarter. Laurel Wealth Advisors LLC grew its stake in shares of IQVIA by 15,755.2% in the second quarter. Laurel Wealth Advisors LLC now owns 779,598 shares of the medical research company’s stock worth $122,857,000 after acquiring an additional 774,681 shares during the period. Finally, JPMorgan Chase & Co. raised its holdings in shares of IQVIA by 22.8% during the second quarter. JPMorgan Chase & Co. now owns 3,126,171 shares of the medical research company’s stock valued at $492,659,000 after purchasing an additional 581,157 shares during the last quarter. Institutional investors own 89.62% of the company’s stock.

IQVIA Stock Down 1.3%

Shares of IQV opened at $166.70 on Friday. IQVIA Holdings Inc. has a 12-month low of $134.65 and a 12-month high of $247.04. The company has a current ratio of 0.75, a quick ratio of 0.70 and a debt-to-equity ratio of 2.09. The company has a market capitalization of $28.39 billion, a PE ratio of 21.21, a price-to-earnings-growth ratio of 1.61 and a beta of 1.37. The business’s 50 day moving average is $223.12 and its 200 day moving average is $209.07.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Thursday, February 5th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.40 by $0.02. IQVIA had a net margin of 8.34% and a return on equity of 30.50%. The firm had revenue of $4.36 billion for the quarter, compared to analysts’ expectations of $4.24 billion. During the same quarter last year, the business posted $3.12 earnings per share. The company’s revenue for the quarter was up 10.3% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. Research analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have weighed in on IQV shares. Robert W. Baird set a $258.00 target price on shares of IQVIA and gave the company an “outperform” rating in a research note on Wednesday, October 29th. Evercore ISI reissued an “outperform” rating on shares of IQVIA in a research report on Thursday, February 5th. Wall Street Zen downgraded IQVIA from a “buy” rating to a “hold” rating in a research note on Saturday, February 7th. TD Cowen increased their price objective on shares of IQVIA from $215.00 to $245.00 and gave the stock a “hold” rating in a research note on Thursday, January 22nd. Finally, Stifel Nicolaus dropped their price target on shares of IQVIA from $273.00 to $220.00 and set a “buy” rating on the stock in a research note on Friday, February 6th. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, IQVIA currently has a consensus rating of “Moderate Buy” and an average target price of $238.20.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.